Academic

A growing number of nanomedicines have been developed for drug delivery via injection into the bloodstream. These nanocarriers transport drug molecules across the physiological environment, reducing toxicity by providing a protective carrier for their payloads. Among various delivery systems, liposomes have emerged as market leaders, with the first follow-on products receiving global regulatory approval. The distribution and elimination kinetics from the bloodstream are influenced by both the physiological environment and the precise composition and quality parameters of the delivery system. To achieve more predictable performance in humans, plasma concentration-time profiles of drugs serve as the primary source of information. However, isolating nanomedicines from plasma presents a challenge, necessitating a combination of various methods and animal testing to understand the complete in vivo lifecycle of the delivery system. This lifecycle is characterized by changes in nanomedicine structure, assembly, and cell interaction. This talk will present various applications and methodologies that enhance our understanding of nanomedicine performance, with the ultimate goal of achieving a more predictable in vivo effect.